Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
New £19.7m Bridgwater health academy gets ‘bat cave’ approval
3+ hour, 19+ min ago (608+ words) The building on Salmon Parade can now be converted Work on a new health and social care training academy could begin before the end of the year, after essential bat mitigation work was approved by councillors. About £19.7m of funding was…...
C-CAMP National Bio Entrepreneurship competition 2026 recognises 15 startups and four student teams
5+ hour, 47+ min ago (509+ words) The winners were announced at the finale held in Bengaluru, in the presence of Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited Fifteen startups and four student teams have emerged as winners of the ninth edition of the C-CAMP National Bio Entrepreneurship…...
Enhertu Shows 14.3-Month PFS in HER2+ Lung Cancer Trial
3+ hour, 10+ min ago (338+ words) Results were presented today during the Presidential Symposium at the IASLC 2026 World Conference on Lung Cancer (#WCLC26) hosted by the International Association for the Study of Lung Cancer in Seoul, South Korea (abstract #PL03.08). In the primary endpoint of PFS, Enhertu monotherapy…...
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
4+ hour, 55+ min ago (1000+ words) AstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to delay disease progression over standard of care in a Phase III trial in this setting Results were presented today during the Presidential Symposium at the IASLC 2026 World Conference on…...
UK microscopy firm expands PH operations with Cavite office
4+ hour, 7+ min ago (230+ words) The company also launched a localized website as part of the expansion, which is focused on manufacturing clusters in Calabarzon and Cebu. Vision Engineering supplies optical and digital systems used for quality control and non-contact measurement. Its products include the…...
The eastward shift in the biotech world: Why India and China could lead the next wave
7+ hour, 32+ min ago (747+ words) China’s advantage is scale across discovery and development, and India in cost-efficiency and innovation footprint. For decades, the global biotechnology map was largely defined by a handful of established centres in the United States, and Europe. Boston, the Bay Area,…...
TAGRISSO?? (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
4+ hour, 10+ min ago (605+ words) Longest survival data ever reported in a global Phase III trial in this setting New data reinforce TAGRISSO as the standard of care and backbone therapy in EGFRm lung cancer across stages These results were presented today during the Presidential…...
5 drugmakers chasing Merck and Moderna in the cancer vaccine race
25+ min ago (1324+ words) Statistics cookies help us to understand how visitors interact with websites by collecting and reporting information anonymously. Marketing cookies allow us to display more relevant ads that are engaging for our users and thereby, they are more valuable for publishers…...
Daily Special: HealthCo Healthcare & Wellness REIT, Proteomics International Laboratories, Titomic, Green360 Technologies, TMK Energy
5+ hour, 38+ min ago (29+ words) Sharecafe Daily Special: HealthCo Healthcare & Wellness REIT, Proteomics International Laboratories, Titomic, Green360 Technologies, TMK Energy...
Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
6+ hour, 47+ min ago (1584+ words) Daiichi Sankyo and AstraZeneca's Enhertu is the first HER2 directed medicine to delay disease progression over standard of care in a phase 3 trial in this setting Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo…...